Abstract
The vaginal route of administration of contraceptive steroids offers a number of advantages over oral or injectable preparations. Firstly, the device can be inserted, removed and replaced by the subject herself without the need of medical or paramedical personnel. The fact that it is in situ can be easily checked which is not always the case with an IUD. The vaginal rings that have been developed have a constant release rate of drug which results in steady plasma levels which is not the case with oral preparations1. The vaginal absorption of the steroid avoids the ‘first pass’ effect of the liver which means that the drug reaches the target organ without having entered the enterohepatic circulation.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Stanczyk, F. Z., Hiro, M., Goebelsmann, U., Brenner, P. F., Lumkin, M. E. and Mishell, D. R. (1975). Radioimmunoassay of serum n-norgestrel in women following oral and intravaginal administration. Contraception, 12, 279
Landgren, B-M., Johannisson, E., Masironi, B. and Diczfalusy, E. (1982). Pharmacokinetic and pharmacodynamic investigations with vaginal devices releasing levonorgestrel at a constant, near zero-order rate. Contraception, 26, 576
Macht, D. I. (1918). The absorption of drugs and poisons through the vagina. J. Pharmacol. Pathol., 10, 509
Hartman, C. G. (1959). The permeability of the vaginal mucosa. Ann. N.Y. Acad. Sci., 83, 857
Folkman, J. and Long, D. M. (1964). Drug pacemakers in the treatment of heart block. Ann. N.Y. Acad. Sci., 111, 857
Dzuik, P. J. and Cook, B. (1965). Passage of steroids through silicone rubber. Endocrinology, 78, 208
Duncan, G. W. Medicated Devices and Methods. U.S. Patent No. 3, 545, 439
Mishell, D. R., Talas, M. and Parlow, A. F. (1970). Contraception by means of Silastic vaginal ring impregnated with medroxyprogesterone acetate. Am. J. Obstet. Gynecol., 107, 100
Mishell, D. R. and Lumkin, M. E. (1970). Contraceptive effect of varying doses of progestogen in Silastic vaginal rings. Fertil. Steril., 21, 9910
Mishell, D. R., Lumkin, M. and Stone, S. (1972). Inhibition of ovulation with cyclic use of progestogen-impregnated intravaginal devices. Am. J. Obstet. Gynecol., 113, 927
Zanartu, J. and Guerrero, R. (1973). Steroid release from polymer vaginal devices. Effect on fertility inhibition. Steroids, 21, 325
Thiery, M., Vandekerckhove, D., Dhont, M., Vermeulen, A. and Decoster, J. M. (1976). The medroxyprogesterone acetate intravaginal Silastic ring as a contraceptive device. Contraception, 13, 605
World Health Organization’s Special Programme of Research, Development and Research Training in Human Reproduction (1979). Intravaginal and intracervical devices for the delivery of fertility regulating agents. J. Steroid Biochem., 11, 461
Gallegos, A. J. (1980). Vaginal steroidal contraception. In Zatuchni, G. et al. (eds.). Research Frontiers in Fertility Regulation. PARFR series on Fertility Regulation, pp. 230–36. ( Hagerstown, Md.: Harper and Row )
Victor, A., Jackanicz, T. M. and Johansson, E. D. B. (1978). Vaginal progesterone for contraception. Fertil. Steril., 30, 631
Johansson, E. D. B., Luukkainen, T., Vartiainen, E. and Victor, A. (1975). The effect of progestin R2323 released from vaginal rings on ovarian function. Contraception, 12, 299
Akinla, O., Lahteenmaki, P. and Jackaniez, T. M. (1976). Intravaginal contraception with the synthetic progestin R2323. Contraception, 14, 671
Jackanicz, T. M. (1981). Levonorgestrel and estradiol release from an improved contraceptive vaginal ring. Contraception, 24, 323
Sivin, I., Mishell, D. R., Victor, A. et al. (1981). A multicentre study of levonorgestrel-oestradiol contraceptive vaginal rings. I - use effectiveness. Contraception, 24, 341
Sivin, I., Mishell, D. R., Victor, A. et al. (1981). A multicentre study of levonorgestrel-oestradiol contraceptive vaginal rings. II - subjective and objective measures of effects. Contraception, 24, 359
Ahren, T., Lithell, H., Victor, A., Vessby, B. and Johansson, E. D. B. (1981). Comparison of the metabolic effects of two hormonal contraceptive methods: an oral formulation and a vaginal ring. II serum lipoproteins and apoliproteins. Contraception, 24, 451
Roy, S., Wilkins, J. and Mishell, D. R. (1981). The effect of a contraceptive vaginal ring and contraceptives on the vaginal flora. Contraception, 24, 481
Liu Quiming, Zheng Kang-Qi, Xu Xiang-hua, Heseh Chung-ming and Chen Xun (1981). Studies on megestrol acetate intravaginal Silastic ring as a new contraceptive device. Reprod. Contracept., 1, 29
Liu Chiming (1983). New long-acting contraceptive delivery system megestrolacetate silicone rubber vaginal rings. Presented at the National Symposium on Long-acting Agents for Contraception, Hangzhou, People’s Republic of China, 14–15 January
World Health Organization’s Task Force on Oral Contraceptives (1982). A randomized double blind study of six combined oral contraceptives. Contraception, 25, 231
World Health Organization’s Task Force on Oral Contraceptives (1982). A randomized double blind study of two combined and two progestogen-only contraceptives. Contraception, 25, 243
World Health Organization’s Task Force on Intrauterine Devices (1983). The Alza T IPCS 52 progesterone releasing IUD. Results of WHO-sponsored randomized clinical trials. Clin. Reprod. Fertil. (In press)
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1984 MTP Press Limited
About this chapter
Cite this chapter
Rowe, P.J. (1984). Steroid-releasing vaginal rings: a review. In: Harrison, R.F., Bonnar, J., Thompson, W. (eds) Fertility and Sterility. Springer, Dordrecht. https://doi.org/10.1007/978-94-015-1308-1_28
Download citation
DOI: https://doi.org/10.1007/978-94-015-1308-1_28
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-015-1310-4
Online ISBN: 978-94-015-1308-1
eBook Packages: Springer Book Archive